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Abstract
Background: Carbonic anhydrase IX (CA IX) is a hypoxia-regulated transmembrane protein over-expressed in various types
of human cancer. Recently, a new peptide with affinity for human carbonic anhydrase IX (CaIX-P1) was identified using the
phage display technology. Aim of the present study is to characterize the binding site in the sequence of CaIX-P1, in order
to optimize the binding and metabolic properties and use it for targeting purposes.
Methodology/Principal Findings: Various fragments of CaIX-P1 were synthesized on solid support using Fmoc chemistry.
Alanine scanning was performed for identification of the amino acids crucial for target binding. Derivatives with increased
binding affinity were radiolabeled and in vitro studies were carried out on the CA IX positive human renal cell carcinoma cell
line SKRC 52 and the CA IX negative human pancreatic carcinoma cell line BxPC3. Metabolic stability was investigated in cell
culture medium and human serum. Organ distribution and planar scintigraphy studies were performed in Balb/c nu/nu mice
carrying subcutaneously transplanted SKRC 52 tumors. The results of our studies clearly identified amino acids that are
important for target binding. Among various fragments and derivatives the ligand CaIX-P1-4-10 (NHVPLSPy) was found to
possess increased binding potential in SKRC 52 cells, whereas no binding capacity for BxPC3 cells was observed. Binding of
radiolabeled CaIX-P1-4-10 on CA IX positive cells could be inhibited by both the unlabeled and the native CaIX-P1 peptide
but not by control peptides. Stability experiments indicated the degradation site in the sequence of CaIX-P1-4-10.
Biodistribution studies showed a higher in vivo accumulation in the tumor than in most healthy tissues.
Conclusions: Our data reveal modifications in the sequence of the CA IX affine ligand CaIX-P1 that might be favorable for
improvement of target affinity and metabolic stability, which are necessary prior to the use of the ligand in clinical
approaches.
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Introduction
Decreased oxygen concentration in solid tumors is known to
cause molecular and phenotypic changes that lead to aggressive
and rapid tumor growth, as well as to poor responsiveness to
chemo- and radiotherapy [1,2]. At the molecular level hypoxia
induces the accumulation of HIF-1a that further activates a series
of target genes, including carbonic anhydrase IX (CA IX) [3,4].
CA IX is a membrane-associated member of the CA zinc
metalloenzyme family, known to be involved in tumorigenic
processes [5]. The protein is over-expressed in various human
tumors and its expression is associated with a poor prognosis [6–
8]. The fact that CA IX is over-expressed in tumors under hypoxic
conditions makes CA IX an attractive candidate for the
development of tumor hypoxia targeting approaches.
Prominent examples of molecules with affinity for human
carbonic anhydrase IX are sulfonamide motifs and monoclonal
antibodies. Sulfonamides can bind CA IX through an interaction
with the active center of the enzyme, however their binding is
characterized by low specificity due to the high homology of the
active centers of different members of the carbonic anhydrase
family [9]. Furthermore, although monoclonal antibodies target-
ing CA IX have been developed and successfully tested in
preclinical and clinical trials [10–12], antibodies often possess
unfavourable pharmacokinetic properties due to their large
molecular size.
Peptides present an attractive alternative to antibodies. Due to
their small size peptides have improved pharmacokinetic proper-
ties, characterized by higher effectiveness of tumor penetration
and rapid blood clearance. Furthermore, peptides do not possess
the immunogenic potential of antibodies, while they are easier and
cheaper to synthesize [13].
Recently we identified a new peptide with specificity for the
extracellular domain of CA IX using the phage display technology.
The peptide CaIX-P1 (YNTNHVPLSPKY) was identified on the
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e38279immobilized extracellular domain of CA IX using a commercial
available Ph.D.12 library [14]. CaIX-P1 was chemically synthe-
sized and tested in vitro for binding affinity, specificity, kinetics and
internalization. In addition, the in vivo behavior of CaIX-P1 was
investigated in biodistribution studies and in vivo blocking
experiments. The results of these studies indicated a specific
binding to human CA IX. Our studies showed a higher
accumulation on the immobilized extracellular domain of CA
IX and on cells strongly over-expressing the target protein. Peptide
binding to the negative control protein EGFR and to negative
control cell lines was reduced to the background level. Further
evidence for specific target binding was found in competition
experiments revealing that the uptake of the radiolabeled ligand
could be competitively abolished by the unlabeled peptide but not
by unspecific competitors. Furthermore, organ distribution studies
in nude mice indicated a higher accumulation in the tumor than in
most healthy organs [14], whereas in vivo blocking using the
unlabeled peptide as competitor led to a significant decrease of
radioligand accumulation. These results indicate that CaIX-P1 is
an attractive candidate for the development of ligands specifically
targeting human CA IX and allow the hypothesis that the peptide
might find application for the improvement of hypoxia targeting
strategies.
However, the transfer of new peptides to clinical applications is
often difficult. One major drawback is the metabolic instability,
which results in serum degradation, decreased tumor to organ
ratios and enhanced background activity. Therefore, further
investigation of the ligand is necessary, prior to its use for clinical
application. In this direction identification of the binding region in
the peptide sequence is of high importance since it could lead to
smaller derivatives with increased tumor penetration and target
affinity, allowing at the same time targeted modifications for
optimization of the metabolic stability. Aim of the present study is
the optimization of the properties of CaIX-P1. To identify the
binding amino acids alanine scanning was performed and various
fragments of the peptide were synthesized and tested for affinity
and specificity on human cancer cells over-expressing CA IX. A
derivative that was identified to possess improved binding
characteristics was further evaluated in vitro and in vivo. The results
of our study indicate molecular modifications that are necessary
for optimization of CA IX targeting strategies and reveal
challenges associated with optimizing phage-display derived
peptides.
Results
CA IX expression in SKRC 52 and BxPC3 cells
The known CA IX positive renal cell carcinoma cell line SKRC
52 and the CA IX negative pancreatic carcinoma cell line BxPC3
were used as positive and negative control target. Prior to the
binding experiments, the expression of CA IX in the two cell lines
was evaluated using real time PCR and western blot analysis. The
analysis demonstrated an expression of CA IX in SKRC 52 cells
but no expression in BxPC3 cells (Figure S1).
Radiolabeling of peptides
The shift in retention times between the labeled and the
unlabeled peptides facilitated separation of the tracer with high
specific activity. As a result specific activities of approximately
50 GBq/mmol for the
125I- and
131I- labeled ligands could be
obtained.
Identification of the binding site in the sequence of CaIX-
P1
To identify the binding site in the sequence of CaIX-P1 and
determine which amino acids are responsible for target affinity,
alanine scanning was performed. For alanine scanning, derivatives
of CaIX-P1 were synthesized with exchange of each amino acid by
alanine. All peptide-derivatives were labeled with
125I and tested
for binding in comparison to the radiolabeled native CaIX-P1 on
CA IX positive renal cell carcinoma SKRC 52 cells (Figure 1).
The results of alanine scanning showed a significant binding
decrease when
3T,
4N,
8L and
12Y( p ,0.05) were exchanged by
alanine. Furthermore, a trend to a binding decrease was noticed
for the amino acids
5H,
8L and
9S. These results indicate that the
amino acids
3T,
4N,
5H,
8L,
9S and
12Y might be important for
CaIX-P1 binding on SKRC 52 cells. To prove this hypothesis, 8-
amino acid fragments of CaIX-P1 were synthesized, labeled with
125I and investigated for binding on target cells. Octapeptides were
chosen because the peptide CaIX-P1-3-10, representing the
middle part of CaIX-P1 is the smallest derivative containing all
amino acids that were considered by alanine scanning to be
important for ligand binding. Comparison after binding saturation
of the
125I-labeled fragments CaIX-P1-1-8 (YNTNHVPL), CaIX-
P1-3-10 (TNHVPLSPy) and CaIX-P1-5-12 (HVPLSPKY) with
the native CaIX-P1 (YNTNHVPLSPKY) peptide revealed that
the fragment CaIX-P1-3-10 had an up to five-fold higher binding
capacity on SKRC 52 cells compared to the leader peptide
(p,0.05). The fragments CaIX-P1-1-8 and CaIX-P1-5-12 showed
a significantly reduced binding activity (Figure 2). For the native
CaIX-P1 and CaIX-P1-3-10 peptide binding was higher after
10 minutes as compared to 30 minutes incubation (Figure 2).
To further investigate the binding site in the sequence of CaIX-
P1, several peptide fragments were synthesized and tested on
SKRC 52 cells. The ratios binding derivative to binding CaIX-P1
are presented in Table 1.
These data indicate that the sequence CaIX-P1-4-10 represents
the shortest derivative with the highest binding capacity on the CA
IX over-expressing cells. CaIX-P1-4-10 had an almost six-fold
binding on SKRC 52 cells compared to the native CaIX-P1
peptide (p,0.05), reaffirming the previous hypothesis that the
binding site in the sequence of CaIX-P1 might be between
3Thr
and
10Pro.
In vitro and in vivo evaluation of CaIX-P1-4-10
Since the peptide CaIX-P1-4-10 showed a significantly higher
binding than CaIX-P1, in vitro kinetics, competition and in-
ternalization studies, as well as in vivo distribution experiments
were performed. Binding kinetics of
125I-CaIX-P1-4-10 in SKRC
52 cells, with incubation periods varying from 10 min to 2 h,
revealed a maximal binding of about 21% applied dose/10
6 cells
after 10 min incubation. Thereafter a time-dependent decrease
was noticed with the bound activity reaching a value of about
1.3% after 2 h incubation. No binding was measured on CA IX
negative BxPC3 cells (Figure 3).
To further verify the binding affinity and specificity, competi-
tion studies were carried out. Co-incubation of
125I-CaIX-P1-4-10
with unlabeled CaIX-P1-4-10 or unlabeled CaIX-P1 on SKRC 52
cells resulted in a concentration dependent inhibition of the
radioligand binding with an inhibition of over 95% at 10
24 mol/L
competitor concentration (p,0.05) (Figure 4A, 4B). The IC50
values were calculated to be 1.3610
27 M when CaIX-P1-4-10
was used as competitor and 1.5610
26 M when CaIX-P1 was used
as competitor. At a competitor concentration of 10
25 mol/L
CaIX-P1-4-10 showed a binding inhibition of about 95% and
CaIX-P1 of about 80% (p,0.05). The negative control competitor
Peptide Binding Carbonic Anhydrase IX
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(Figure 4C).
Internalization experiments of CaIX-P1-4-10
To distinguish between surface bound and internalized peptide,
in vitro internalization was investigated in SKRC 52 cells. After
10 min incubation with
125I-CaIX-P1-4-10 at 37uC, the in-
ternalized radioactivity was measured to reach the level of about
20% of the total bound activity, while after 60 min incubation
17% of the total uptake was found to be internalized into the
SKRC 52 cells. With time progression both membrane bound and
internalized radioactivity decreased. Internalization experiments
were also performed at 4uC demonstrating a significant reduction
of internalized activity, leading to reduction of total binding
(p,0.05) (Figure 5).
Figure 1. Alanine scanning of
125I-labeled CaIX-P1 peptide on CA IX positive human renal cell carcinoma SKRC 52 cells. Ratio binding-
derivative to binding-CaIX-P1. Mean values and standard deviation.
doi:10.1371/journal.pone.0038279.g001
Figure 2. Binding of the CaIX-P1 peptide fragments CaIX-P1-1-8, CaIX-P1-3-10 and CaIX-P1-5-12 on CA IX positive human renal cell
carcinoma SKRC 52 cells. Mean values and standard deviation.
doi:10.1371/journal.pone.0038279.g002
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Biodistribution studies of
131I-labeled CaIX-P1-4-10 were
performed in nude mice, carrying subcutaneous SKRC 52
tumors. The results of these studies showed a higher uptake in
the tumor than in most healthy organs, such as heart, spleen, liver,
muscle and brain after 15 min and 60 min circulation in the
animals. Increased activities were measured for blood and kidney.
Between 15 min and 60 min a binding decrease was noticed in
both tumor and healthy tissues. The decrease in the tumor was
lower compared to the other organs, resulting in an increase of the
tumor to organs ratios (Table 2). Thereafter, a strong decrease in
all organs was noticed (Figure 6).
Planar scintigraphy
In vivo planar scintigraphy studies were performed in nude mice,
carrying subcutaneously SKRC 52 tumors in the upper part of the
hind leg. Planar scintigraphy showed a tumor visualization at
10 min p.i. Furthermore, the planar images demonstrated a rapid
renal elimination but also a high background noise (Figure 7).
Table 1. Various fragments of CaIX-P1 were tested on CA IX positive human renal cell carcinoma SKRC 52 cells.
Peptide Sequence Ratio binding-derivative to binding-CaIX-P1 (10 min)
CaIX-P1 YNTNHVPLSPKY 1
CaIX-P1-3-6 TNHVy 0.29
CaIX-P1-3-7 TNHVPy 0.60
CaIX-P1-3-8 TNHVPLy 0.76
CaIX-P1-3-9 TNHVPLSy 1.57
CaIX-P1-3-10 TNHVPLSPy 5.40
CaIX-P1-4-7 NHVPy 0.79
CaIX-P1-4-8 NHVPLy 0.82
CaIX-P1-4-9 NHVPLSy 2.62
CaIX-P1-4-10 NHVPLSPy 5.84
CaIX-P1-5-9 HVPLSy 0.06
CaIX-P1-5-12 HVPLSPKy 0.10
CaIX-P1-6-10 VPLSPy 0.25
CaIX-P1-8-10 LSPy 0.04
Ratio binding-fragment to binding-CaIX-P1.
doi:10.1371/journal.pone.0038279.t001
Figure 3. In vitro kinetics of
125I-CaIX-P1-4-10 on SKRC 52 and BxPC3 cells. Incubation was performed for time periods varying from 10 min
to 120 min. Mean values and standard deviation.
doi:10.1371/journal.pone.0038279.g003
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125I-labeled CaIX-P1-4-10 on SKRC 52 cells
The decreasing binding kinetics of the native CaIX-P1 peptide
was explained in the initial study by an intracellular degradation of
the peptide [14]. To investigate this hypothesis for CaIX-P1-4-10
the medium stability of this peptide was investigated after
incubation on SKRC 52 and BxPC3 cells. Medium stability
studies demonstrated a time dependent degradation of CaIX-P1-
4-10 on SKRC 52 cells. In particular, only 30% of the activity was
measured after 60 min incubation, while at 120 min incubation
radiolabeled CaIX-P1-4-10 was completely degraded (Figure 8A).
No radioligand degradation was shown in CA IX negative BxPC3
cells (Figure 8B).
To evaluate the degradation site in the sequence of CaIX-P1-4-
10, HPLC chromatograms of all C-terminal fragments of the
peptide were analyzed (Figure 8C).
The HPLC analysis of the C-terminal fragments of CaIX-P1-4-
10 was compared to the chromatograms of the cell medium
supernatants. This comparison revealed that the peptide was
degraded between
6S and
7P and the last fragment was Py
(Figure 8D).
Stability in human serum
Metabolic stability of CaIX-P1-4-10 was also investigated in
human serum. The results of serum stability experiments revealed
slow time-dependent peptide degradation. Serum half life of
CaIX-P1-4-10 was calculated to be 1.5 h.
Discussion
Carbonic anhydrase IX (CA IX) is a transmembrane protein,
linked to cancer development [15–18] and considered to be an
intrinsic marker of tumor hypoxia. The protein distribution in
human tissues exhibits a unique pattern that enables designation of
CA IX as a tumor-associated protein [19], making it an attractive
structure for specific targeting approaches.
Recently, we identified a new peptide (CaIX-P1) with affinity
for the extracellular domain of human CA IX using phage display
[14]. The peptide evaluation indicated that CaIX-P1 might be an
attractive ligand for targeting CA IX in tumors. Aim of the present
study is to further characterize the CaIX-P1 peptide, identify the
amino acids that are essential for target binding and optimize its
affinity and metabolic characteristics.
Figure 4. Displacement of bound
125I-CaIX-P1-4-10 by the unlabeled CaIX-P1 (A) and the unlabeled CaIX-P1-4-10 (B) peptide at
various concentrations on SKRC 52 cells. (C) Specific binding of
125I-CaIX-P1-4-10 on SKRC 52 cells. Non specific binding was determined in the
presence of 10
25 M unlabeled CaIX-P1-4-10 and CaIX-P1. Octreotide was used at the same concentration (10
25 M) as a negative control competitor.
Mean values and standard deviation.
doi:10.1371/journal.pone.0038279.g004
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alanine scanning was performed in order to identify single amino
acids that might be important for target binding. Thereafter,
various derivatives and fragments were synthesized and tested for
binding. The derivative that showed the highest binding capacity
was evaluated for binding kinetics, competition, internalization
and biodistribution, as well as for metabolic stability using the well
established, CA IX over-expressing cell line SKRC 52 [20].
Our results indicate that the amino acids
3T,
4N,
5H,
8L,
9S and
12Y are important for the target affinity of CaIX-P1. This
hypothesis is supported by the evaluation of three octapeptides
derived from the sequence of CaIX-P1, demonstrating that the
fragment CaIX-P1-3-10, which includes all these amino acids had
a strongly increased binding affinity. In contrary, fragments that
lacked more than one of these amino acids showed a significant
binding decrease. These results are in concert with further studies
showing that peptide fragments lacking more than 2 amino acids,
Figure 5. Binding and internalization of
125I-CaIX-P1-4-10 in SKRC 52 cells. Cells were incubated with the radioligand for 10 min, 30 min,
60 min, 120 min and 240 min at 37uCo ra t4 uC. Mean values and standard deviation.
doi:10.1371/journal.pone.0038279.g005
Figure 6. Organ distribution of
131I-labeled CaIX-P1-4-10 in female Balb/c nu/nu mice carrying SKRC 52 tumors. Incubation was
performed for 15 min, 60 min and 240 min (3 animals per experiment).
doi:10.1371/journal.pone.0038279.g006
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capacity.
Since
12Y is indicated to be important for ligand binding, an
issue that needs to be addressed is the influence of radioiodination
on the properties of the peptide. The addition of one radioiodine
atom to large molecules, such as antibodies does not usually affect
their activity, mainly because the iodine substituent is too small to
induce significant conformational changes [21]. However, the
incorporation of an iodine atom in small peptides may have
negative effects on their binding properties, especially for
oligopeptides. Consequently, the pharmacokinetic properties of
each individual ligand should be further investigated to charac-
terize the functional integrity of the ligands after iodination.
Characterization of various peptide fragments revealed a mol-
ecule consisting of 7 amino acids and a C-terminal D-tyrosine
residue with the highest binding capacity (CaIX-P1-4-10). To
determine the characteristics of the best binder a detailed
evaluation was performed. In vitro experiments demonstrated an
enhanced accumulation of CaIX-P1-4-10 on CA IX positive cells
but no binding on CA IX negative cells. However, kinetic studies
showed a time dependent binding decrease. Similar kinetics have
been described for both the native CaIX-P1 peptide [14], but also
for monoclonal antibodies targeting human carbonic anhydrase
IX [22]. The time dependent binding reduction was explained by
processes of degradation, leading to radioactive products that are
excreted by the cells. To prove this hypothesis internalization
experiments and HPLC analysis of cell culture medium after
radioligand incubation on CA IX positive and CA IX negative
cells were performed. The internalization experiments revealed
a slight cellular uptake, whereas the HPLC chromatograms
demonstrated a peptide degradation. No degradation was noticed
when the peptide was incubated with CA IX negative cells. These
results together strengthen the hypothesis of a peptide uptake in
CA IX positive cells, followed by cellular degradation and
externalization of radiolabeled products, which results in a time
dependent activity decrease.
Evidence for the specificity of CaIX-P1-4-10 was shown in
competition experiments. These studies revealed a concentration
dependent inhibition of radioligand binding, when both the
unlabeled CaIX-P1-4-10 peptide, but also the native CaIX-P1
ligand was used as competitor. The binding specificity was further
indicated by experiments revealing no reduction of radioligand
binding when the negative control competitor octreotide was used.
In vivo distribution of CaIX-P1-4-10 showed a higher accumu-
lation in tumor than in most healthy tissues, but also demonstrated
increased background levels, result which correlated with planar
scintigraphy images. Planar scintigraphy indicated a visualization
of the tumor but also demonstrated a rapid renal elimination.
High background noise is a major drawback for the use of ligands
for imaging applications. The metabolic properties of the peptide
are essential in this respect. In particular, most linear peptides
reveal short serum half lives, as a result of rapid proteolytic
degradation. Metabolic instability leads to circulation of products
that either lack target affinity or inhibit further ligand binding.
Investigation of the metabolic properties of CaIX-P1-4-10
revealed an increased stability in human serum (serum half life
1.5 h) compared to the native CaIX-P1 peptide (serum half life
25 min). However, our results indicated a rapid cellular degrada-
tion followed by radioactivity externalization. The combination of
rapid cellular degradation and serum instability might be re-
sponsible for the high blood background. Therefore, further
improvement of the metabolic properties of CaIX-P1-4-10 is still
necessary. Possible chemical methods that can be applied in this
respect include peptide cyclization [23], targeted exchange of
Table 2. Tumor-to-organ ratios calculated from the organ
distribution of
131I-CaIX-P1-4-10 in female Balb/c mice
carrying subcutaneously transplanted SKRC 52 tumors (n=3
animals per time point).
Tumor to organ ratio 15 min 60 min 240 min
Blood 0.63 0.69 0.67
Heart 1.63 2.09 1.84
Lung 0.86 0.88 0.92
Spleen 1.06 1.39 1.35
Liver 1.32 1.65 1.49
Kidney 0.56 0.73 0.61
Muscle 3.36 3.39 2.53
Brain 13.87 14.91 15.10
doi:10.1371/journal.pone.0038279.t002
Figure 7. Planar scintigraphy of
125I-CaIX-P1-4-10 in SKRC 52 tumor bearing mice. Tumors were transplanted at the right hind leg of the
animals (n=2). Images were obtained at 10 min and 30 min.
doi:10.1371/journal.pone.0038279.g007
Peptide Binding Carbonic Anhydrase IX
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e38279amino acids with D-amino acids, which are not recognized by
serum proteases [24] or grafting the binding motif into a stable
scaffold structure [25].
In conclusion, our study reveals modifications in the sequence of
the human carbonic anhydrase IX binding peptide CaIX-P1 that
might increase its target affinity. The in vitro evaluation of CaIX-
P1-4-10 demonstrates improved binding and metabolic character-
istics. However, organ distribution experiments still reveal low
tumor-to-blood ratios and increased background noise, which is
not favorable for imaging applications. Therefore, although our
studies provide molecules with optimized in vitro properties, further
experiments are necessary for generation of peptide-based ligands
specifically targeting human carbonic anhydrase IX.
Materials and Methods
Chemical reagents and solvents
All reagents and solvents were purchased from commercial
suppliers and were used without further purification.
Cell lines
All cell lines were cultivated at 37uC in a 5% CO2 incubator.
The human renal cell carcinoma cell line SKRC 52 was obtained
by O. Boerman (Univ. of Nijmegen, The Netherlands). SKRC 52
was cultured in RPMI-1640 with GlutaMAX (Invitrogen) contain-
ing 10% (v/v) fetal calf serum (Invitrogen). BxPC3 was cultured in
RPMI-1640 with extra D-Glucose (4.5 g/L) (Invitrogen) contain-
ing 10% (v/v) fetal calf serum.
Peptide Synthesis
Peptides were prepared using standard Fmoc-based solid-phase
peptide synthesis in an Applied Biosystems 433A synthesizer.
0.05 mmol Tentagel R RAM (Rapp Polymere Tu ¨bingen,
Germany ) with a loading of 0.19 mmol/g and 0.5 mmol (10
eq.) of Fmoc-protected amino acids with the following side-chain
protecting groups were used: tert-butyl (tBu) for Asp, Glu, Ser, Thr
and Tyr, tert-butyloxycarbonyl (Boc) for Lys and Trp, trityl (Trt)
for Asn, Gln and His, and 2,2,4,6,7-pentamethyldihydrobenzo-
Figure 8. In vitro stability studies of
125I-CaIX-P1-4-10 on (A) SKRC 52 cells and (B) BxPC3 cells. (C) HPLC chromatograms of all C-terminal
fragments of CaIX-P1-4-10. (D) HPLC Chromatogram of C-terminal fragments of CaIX-P1-4-10 and HPLC Chromatogram of supernatant in cell media
of SKRC 52 cells are superimposed.
doi:10.1371/journal.pone.0038279.g008
Peptide Binding Carbonic Anhydrase IX
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e38279furan-5-sulfonyl (Pbf) for Arg. The synthesis cycle of the Applied
Biosystems 433A synthesizer consisted of: 1) Fmoc cleavage: 20%
piperidine/DMF, 2) NMP washings, 3) coupling: Fmoc-AA-OH/
HBTU/DIPEA/mmol peptidyl-resin 10/9/20/1, 8 min, 4) NMP
washings.
Cleavage from the resin was performed with 95:2.5:2.5 TFA/
water/triisopropylsilane for 1 h at room temperature and sub-
sequent precipitation with cold diethyl ether. After a second
precipitation with diethylether the residue was dried under
reduced pressure. Purification of the synthesized peptides was
performed by preparative RP-HPLC separation on a Gilson 321
pump HPLC system (Gilson Inc., Middleton, WI, USA) using a X-
Bridge BEH C18 5 mm column (196150 mm; Waters Corp.,
Millford Massachusetts, USA) with a gradient elution from 0.1%
TFA in water to 0.1% TFA in acetonitrile, 0–35%B in 15 min
(flow rate: 20 mL/min, absorbance: l=214 nm).
HPLC analysis
Analytical reversed-phase high-performance liquid chromatog-
raphy (RP-HPLC) was performed on an Agilent 1100 HPLC
system using a Chromolith Performance RP-18e column
(10063 mm; Merck AG Darmstadt, Germany) eluted with a linear
gradient (eluent A: 0.1% TFA in water; eluent B: 0.1% TFA in
acetonitrile; flow rate: 2 mL/min, absorbance: l=214 nm).
HPLC-MS analysis
All products of the peptide synthesis were further characterized
by LC/MS using an Orbitrap Mass Spectrometer (Exactive,
Thermo Fisher Scientific) coupled to an Agilent 1200 HPLC
system on a Hypersil Gold C18 column (2.16200 mm, 1.9m;
Thermo Scientific, Bremen, Germany) eluted with a linear
gradient (eluent A: 0.1% TFA in water; eluent B: 0.1% TFA in
acetonitrile; 0–100% B in 30 min at 60uC, flow rate: 0.2 mL/min,
absorbance: l=214 nm). Full scan single mass spectra (ESI,
positive mode) were obtained by scanning from m/z=200–4000.
Radiolabeling of peptides
Radiolabeling with iodine-125 or iodine-131 was conducted at
the tyrosine moiety of the peptide using the chloramine-T method
a peptide solution in water (1 mM, 5 mL, 5 nmol) was added to
phosphate buffer (0.25 M, pH 7.5, 25 mL). A solution of 1–
15 MBq
125I-NaI or
131I-NaI in 10 mM NaOH was added and the
labelling reaction was started by addition of an aqueous
chloramine-T solution (10 mM, 10 mL). After 30 s, the labeling
reaction was quenched by adding a saturated aqueous solution of
methionine (10 mL).
Radio-HPLC
Radio-HPLC was performed on an Agilent 1100 HPLC system
equipped with a radioactivity detector (GABI Star, Raytest
GmbH, Straubenhardt, Germany) using a Chromolith Perfor-
mance RP-18e column (10063 mm; Merck AG Darmstadt,
Germany) eluted with a linear gradient (eluent A: 0.1% TFA in
water; eluent B: 0.1% TFA in acetonitrile; 0–30% B in 10 min,
flow rate: 2 mL/min).
Semi-preparative radio-HPLC separations were conducted on
a Gyncotech P580 instrument equipped with a Shimadzu SPD 6-
A multi-wavelength detector using a Chromolith performance RP-
18e column (4.66100 mm; Merck AG Darmstadt, Germany)
eluted with a gradient (eluent A: 0.1% TFA in water; eluent B:
0.1% TFA in acetonitrile; 0–35% B in 10 min, flow rate: 2 mL/
min, absorbance: l=214 nm).
In vitro binding experiments
For binding experiments 5610
5 SKRC 52 or BxPC3 cells were
seeded into 6-well plates and cultivated in 3 mL of incubation
medium at 37uC for 24 h. After cell blocking with RPMI 1640
(without FCS) containing 1% BSA, the medium was replaced with
1 mL of fresh medium (without FCS) containing 0.8–
1.2610
6 cpm of
125I-labeled peptide and incubation was per-
formed for time periods varying from 10 min to 2 h at 37uC. To
determine specific versus nonspecific binding, the cells were
incubated with unlabeled competitors at concentrations varying
from 10
24 to 10
210 mol/L. Octreotide was used as negative
control competitor. After incubation the medium was removed
and the cells were washed three times with 1 mL ice cold PBS in
order to remove the unbound radiolabeled peptide. Subsequently,
the cells were lysed with 0.5 mL NaOH 0.3 mol/L and the
radioactivity was measured with a c-counter. Bound radioactivity
was calculated as percentage applied dose per 10
6 cells. CA IX
negative BxPC3 cells were used as negative control.
Internalization studies
Subconfluent cell cultures of SKRC 52 cells were incubated
with
125I-labeled peptide for 10, 30, 60, 120 and 240 min at 37uC
and 4uC. Cellular uptake was stopped by removing the medium
and washing three times with 1 mL PBS. Subsequently, cells were
incubated with 1 mL of glycine-HCl, 50 mmol/L in PBS (pH 2.2)
for 10 min at room temperature in order to remove the surface
bound activity. The cells were then washed with 3 mL of ice-cold
PBS and lysed with 0.5 mL of NaOH 0.3 mol/L. The surface and
the internalized radioactivity were measured with a c-counter and
calculated as % applied dose/10
6 cells.
In vitro stability
125I-labeled peptide was incubated at 37uC on SKRC 52 and
BxPC3 cells. At time points varying from 10 min to 2 h aliquots
were taken and centrifuged for 5 min at 13,000 rpm. The
supernatant was analyzed by HPLC with H2O:CH3CN, 0–30%
in 10 min.
Serum stability assay
Metabolic stability was investigated in human serum (Sigma
Aldrich, H4522). 5 MBq of radiolabeled peptide was dissolved in
human serum (500 mL) and incubated at 37uC. The stability of the
labeled peptide was monitored by analyzing aliquots (25 ml) via
radio-HPLC at selected time points.
Real time quantitative PCR
Total cellular RNA was isolated from confluent SKRC 52 and
BxPC3 cells in 75 cm
2 cell culture flasks using the Trizol method
(TRIzol Reagent, Invitrogen). RNA extraction was carried out
with a standard phenol-chloroform extraction and the concentra-
tion was measured with a NanoDrop spectrophotometer (ND-
1000 PeqLab Biotechnologie GmbH, Germany). 500 ng was
transcribed into DNA using M-MLV reverse transcriptase,
50 pmol random hexamer and 100 pmol of oligo(dT) primers
(Promega, Madison, WI, USA). Quantification of relative mRNA
transcript levels for CA IX was assessed on a StepOnePlus
TM
Real-Time PCR System (Applied Biosystems), applying the
TaqMan methodology. Normalization was performed using
GAPDH as housekeeping gene. Primers were obtained from
Applied Biosystems (Foster City, CA, USA).
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SKRC 52 and BxPC3 cells were grown to 80% confluency.
Cells were washed twice with 10 ml ice-cold PBS pH 7,4 and
scraped with a cell scraper. The lysate was transferred and
centrifuged for 3 min at 1000 rpm. The pellet was washed once
with 5 mL PBS and centrifuged for 3 min at 1000 rpm. The pellet
was taken up in 2 mL of 1% Triton X-100. This mixture was
centrifuged for 10 min at 2700 rpm.
Supernatant was collected for Western Blotting assay. Proteins
were transferred from a polyacrylamide gel to a nitrocellulose
membrane with a Mini Trans-Blotter (100 V for 90 min) in
transfer buffer. After transfer, non-specific binding sites were
blocked for 1 h with 5% non-fat milk powder in TBST buffer at
room temperature. Rabbit IgG monoclonal anti-human CA IX
antibody (abcam, ab108351; 1:1000 dilution) was used as primary
antibody. This was diluted in blocking buffer and incubated with
the membrane overnight at 4uC. After washing in TBST, the
nitrocellulose membrane was incubated with horseradish perox-
idase conjugated antibody (R&D Systems, HAF008; 1:1000
dilution) in blocking buffer at room temperature for 60 min. For
the loading control, Anti-COX IV antibody (abcam, ab14744;
1:5000 dilution) was used as primary antibody and for the
secondary antibody Polyclonal Goat Anti-Mouse (DakoCytoma-
tion, P 0447; 1:1000 dilution) was used. Antibody binding was
determined using the enhanced chemiluminescence detection
system according to the manufacturer’s instructions. Exposures
were recorded on hyperfilms for 10 sec to 3 min.
In vivo organ distribution
Organ distribution studies were performed in 9-week-old female
Balb/c nu/nu mice, carrying subcutaneously transplanted SKRC
52 tumors. Animals were obtained from Charles River WIGA and
housed in VentiRacks (BioZone Global). For tumor transplanta-
tion, SKRC 52 cells were grown to 90% confluence, harvested
with PBS/ethylene diamine tetraacetic acid, resuspended in
Falcon Matrigel-Matrix (BD) and kept on ice. 200 mlo f
Matrigel-Matrix cell suspension were injected subcutaneously into
the anterior region of the mouse trunk and the tumors were grown
to a size of 1.0 cm
3.
131I-labeled CaIX-P1-4-10 was injected into
the tail vein of the animals (approximately 1 MBq) and at 15 min,
60 min and 240 min after injection the animals were sacrificed.
Tumor, blood and selected tissues (heart, spleen, liver, kidney,
muscle, intestinum and brain) were removed, drained of blood,
weighed and the radioactivity was measured in a c-counter (LB
951G; Berthold Technologies). Also 3 aliquots of the tracer
solution used for injection were measured. The organ uptake was
calculated as percentage injected dose per gram tissue (% ID/g).
All animal experiments were carried out in conformity with
German law for protection of animals and are in compliance with
European laws. Study approval was received by the Regierung-
spra ¨sidium Karlsruhe, Abteilung 3, Baden-Wu ¨rttemberg, Ger-
many, File reference: 35-9185.81/G-132/04.
In vivo planar scintigraphy
Planar scintigraphy studies were performed in two Balb/c nu/
nu mice, carrying subcutaneously transplanted SKRC 52 tumors.
A cell suspension of 6610
6 cells in OPTI-MEM (Gibco, Invitrogen
Life Technologies) was injected subcutaneously into the hind leg of
the animals and the tumors were grown to a size of 1.0 cm
3.
125I-
labeled CaIX-P1-4-10 peptide was injected into the tail vein of the
animals (approximately 5 MBq) and at 10 min and 30 min p.i.
planar scintigraphic images were acquired using a Gamma Imager
(Biospace Lab)
Statistics
Data were analyzed employing the paired two-tailed Student t-
test and significance was assumed at P,0.05.
Supporting Information
Figure S1 Western Blot and RT-PCR analysis of SKRC
52 and BxPC3 cells. Carbonic Anhydrase IX is expressed in the
form of 54 and 58 kDa protein bands. COX IV was a loading
control.
(TIF)
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